Pictured: Chicago landscape oncology collage/Nicole Bean for BioSpace

图为：芝加哥风景肿瘤学学院/NicoleBean for BioSpace

The American Society of Clinical Oncology annual meeting kicks off today in Chicago, with several companies releasing highly anticipated abstracts ahead of time. Here are some that caught our attention:

美国临床肿瘤学会年会今天在芝加哥开幕，几家公司提前发布了备受期待的摘要。以下是一些引起我们注意的问题：

Targeted Oncology

靶向肿瘤学

Making headlines, Merus experienced a run on its stock with shares rising one-third last Friday after it announced data from a Phase II study indicating that its bispecific antibody petosemtamab in combination with immunotherapy Keytruda produced a 67% response rate in head and neck cancer. The results will be presented at ASCO as a rapid oral abstract session on June 3 at 8 a.m.

上周五，Merus公布了一项II期研究的数据，表明其双特异性抗体petosemtamab联合免疫疗法Keytruda治疗头颈癌的有效率为67%，该公司股价上涨三分之一，成为头条新闻。结果将于6月3日上午8点在ASCO上以快速口头摘要的形式呈现。

in room E450b..

在E450b房间。。

“Petosemtamab in combination with pembrolizumab (Keytruda) has demonstrated clinically meaningful activity in first line head and neck cancer, with a 67% response rate overall, observed across tumor PD-L1 expression levels and HPV status and with encouraging safety,' said Bill Lundberg, the president and CEO of Merus, in a press release ahead of the presentation..

Merus总裁兼首席执行官比尔·伦德伯格（BillLundberg）在演讲前的新闻稿中说：“佩托司他单抗联合派姆单抗（Keytruda）在一线头颈癌中显示出临床上有意义的活性，总体有效率为67%，在肿瘤PD-L1表达水平和HPV状态下观察到，并且具有令人鼓舞的安全性。”。。

Analysts from William Blair reported confidence in the results, writing in a report: “This unprecedented level of activity in metastatic head and neck cancer patients sets petosemtamab as the most effective combination partner for Keytruda in head and neck cancer patients.” Merus plans to initiate a Phase III study later this year..

威廉·布莱尔（WilliamBlair）的分析师在一份报告中表示，他们对结果充满信心：“转移性头颈癌患者的这种前所未有的活性水平，使佩托司单抗成为头颈癌患者Keytruda最有效的联合用药伙伴。”Merus计划在今年晚些时候启动一项III期研究。。

CAR-T

CAR-T

Following CAR-T therapy Carvykti’s recent expansion into second line treatment for multiple myeloma, Legend Biotech and Johnson & Johnson are scheduled to present clinical data from the Phase II multicohort CARTITUDE-2 study evaluating the treatment’s safety and efficacy in various multiple myeloma treatment settings and patient populations (abstract #7535, #7505)..

在CAR-T治疗后，Carvykti最近扩展到多发性骨髓瘤的二线治疗，Legend Biotech和Johnson＆Johnson计划提供II期Multichort CARTITUDE-2研究的临床数据，评估该治疗在各种多发性骨髓瘤治疗环境和患者人群中的安全性和有效性（摘要#7535，#7505）。。

Carvykti is the first and only B-cell maturation antigen (BCMA)-targeted therapy approved to treat patients with multiple myeloma as early as the first relapse. It was approved by the FDA on April 5 for adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.

Carvykti是第一个也是唯一一个被批准用于治疗多发性骨髓瘤患者的B细胞成熟抗原（BCMA）靶向治疗，早在第一次复发时。FDA于4月5日批准用于复发或难治性多发性骨髓瘤的成年患者，这些患者至少接受过一种治疗方案，包括蛋白酶体抑制剂和免疫调节剂，并且对来那度胺无效。

“While we expect the updates to be incremental to Legend’s stock, we believe they will further support the use of BCMA CAR-T cell therapies in the early-line setting,” William Blair analyst Sami Corwin wrote in a report..

威廉·布莱尔（WilliamBlair）分析师萨米·科尔温（SamiCorwin）在一份报告中写道：“虽然我们预计这些更新将增加联想的库存，但我们相信它们将进一步支持在早期使用BCMA CAR-T细胞疗法。”。。

Emerging Oncology and Immunotherapies

新兴肿瘤学和免疫疗法

On June 3, researchers will be presenting Phase II data on Pfizer and Genmab’s Tivdak (tisotumab vedotin) in head and neck squamous cell carcinoma. Analysts from Leerink Partners were encouraged by the data, positing that they “could see antibody drug-conjugates (ADCs) eventually replace chemotherapy in [the] head and neck cancer treatment paradigm, particularly in the second line space,” according to a report..

6月3日，研究人员将介绍辉瑞和Genmab的Tivdak（tisotumab vedotin）治疗头颈部鳞状细胞癌的II期数据。Leerink Partners的分析师对这些数据感到鼓舞，他们认为“在头颈部癌症治疗模式中，特别是在二线领域，他们“可能会看到抗体-药物偶联物（ADC）最终取代化疗”。。

Additionally, analysts “would be keen to see detail on the tolerability, particularly the avoidance of bleeding events, which had been a concern in previous studies evaluating tisotumab vedotin in head and neck cancer,” according to the report.

此外，根据该报告，分析人士“希望了解耐受性的细节，特别是避免出血事件，这在之前评估tisotumab vedotin治疗头颈癌的研究中一直是一个问题”。

“[Immunotherapies] have the potential to change the lives of patients by changing progressive cancer into a stable disease associated with improved overall survival,” said Paul Peter Tak, president & CEO of Candel Therapeutics, which will present data on its immunotherapy candidate CAN-2409 (ASCO abstract #8634).

Candel Therapeutics总裁兼首席执行官保罗·彼得·塔克（Paul Peter Tak）表示：“[免疫疗法]有可能通过将进行性癌症转变为与总体生存率提高相关的稳定疾病来改变患者的生活，该公司将提供其免疫治疗候选药物CAN-2409（ASCO摘要#8634）的数据。

Tak told BioSpace the data show that in non-small cell lung cancer patients with progressive disease despite immune checkpoint inhibitor therapy, two administrations of CAN-2409 + valacyclovir resulted in a median overall survival of 20.6 months. This compares to the median overall survival of 11.6 months observed with the standard of care docetaxel-based chemotherapy in a similar patient population..

Tak告诉BioSpace，数据显示，尽管进行了免疫检查点抑制剂治疗，但非小细胞肺癌患者的进展性疾病中，两次CAN-2409+伐昔洛韦治疗的中位总生存期为20.6个月。相比之下，在类似患者人群中，以多西紫杉醇为基础的标准化疗观察到的中位总生存期为11.6个月。。

Another abstract highlighted by Leerink Partners is Nanobiotix’s Study 1100 (ASCO abstract #6035). The company is evaluating NBTXR3, which is a radioenhancer composed of functionalized hafnium oxide crystalline nanoparticles, and stereotactic body radiation therapy followed by PD-1 inhibitors nivolumab or pembrolizumab in patients with advanced solid tumors.

Leerink Partners强调的另一个摘要是Nanobiotix的研究1100（ASCO摘要#6035）。该公司正在评估NBTXR3，这是一种由功能化氧化铪晶体纳米粒子组成的放射增强剂，以及立体定向放射治疗，然后是PD-1抑制剂nivolumab或pembrolizumab治疗晚期实体瘤患者。

Leerlink noted the “concept of reconstituting some sensitivity to anti-PD-1 therapy in patients who have progressed” is especially of note, considering that most attempts to do so have so far failed. The report adds that analysts are interested in seeing how the company moves forward by teasing out signals from its “hypothesis-generating dataset.”.

Leerlink指出，“在进展的患者中重建对抗PD-1治疗的某些敏感性的概念”尤其值得注意，因为迄今为止大多数尝试都失败了。该报告补充说，分析师有兴趣通过从其“产生假设的数据集”中挑出信号，看看该公司如何取得进展。

Mollie Barnes is a freelance science writer. Reach her at mollie@100yearsco.com. Follow her on Threads and Instagram @shejustlikedtogo or LinkedIn. See more of her work at molliebarnes.contently.com.

莫莉·巴恩斯是一位自由撰稿人。联系她的电话mollie@100yearsco.com.在帖子和Instagram@shejustlikedtogo或LinkedIn上关注她。有关她的更多作品，请访问molliebarnes.contently.com。